VALDOXAN AFTER ACUTE CORONARY SYNDROME CONCURRENT WITH DEPRESSION
- 作者: Kotov A.1
-
隶属关系:
- A.A. Ostroumov City Clinical Hospital Thirty-Three
- 期: 卷 25, 编号 4 (2014)
- 页面: 32-35
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115905
- ID: 115905
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The use of Valdoxan after acute coronary syndrome concurrent with depression leads to considerable clinical improvement.
全文:
参考
- Всемирная организация здравоохранения. Доклад о состоянии здравоохранения в мире. Нью-Йорк, 2001.
- Иванов С.В. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике (результаты Российского мультицентрового исследования «ХРОНОС») // Психиатрия и психофармакотерапия. - 2009; 11 (6): 14-7.
- Краснов В.Н. Депрессии и сердечно-сосудистые заболевания // Практ. врач. - 2002; 2: 31-2.
- Ariyo A., Haan M., Tangen C. et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group // Circulation. - 2000; 102 (15): 1976-80.
- de Bodinat C., Guardiola-Lemaitre B., Mocaër E. et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development // Nature Reviews Drug Discovery. - 2010; 9: 628-42.
- Engel B., Talan M. Diurnal variation in central venous pressure // Acta. Physiol. Scand. - 1991; 141: 273-8.
- Kennedy S. Agomelatine. Efficacy at Each Phase of Antidepressant Treatment // CNS Drugs. - 2009; 23 (2): 41-7.
- Kennedy S., Rizvi S. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. Review Article Department of Psychiatry, University Health Network, Toronto, Ontario, Canada. 2010 Jun;24(6):479-99. doi: 10.2165/11534420-000000000-00000. PMID: 20192279 [PubMed - indexed for MEDLINE]
- Lee Y., Chen H., Hsiao G. et al. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo // J. Pineal Res. - 2002; 33: 72-80.
- Montgomery S., Kennedy S., Burrows G. et al. Absence of discontinuation symptoms with agomelatine and occurence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study // Int. Clin. Psychopharmacol. - 2004; 19 (5): 271-80.
- Portaluppi F., Montanari L., Bagni B. et al. Circadian rhythms of atrial natriuretic peptide, blood pressure and heart rate in normal subjects // Cardiology. -1989; 76: 428-32
- Qurea-Salva M., Lemoine P., Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. 2010 Apr; 25(3):222-9. doi: 10.1002/hup.1112. Sleep Unit, Raymond Poincaré Hospital, Garches, APHP, France. PMID: 20373473 [PubMed - indexed for MEDLINE]
- Rudisch B. Nemeroff C. Epidemiology of comorbid coronary artery disease and depression // Biol. Psychiatry. - 2003; 54 (3): 227-40
- Stahl S., Fava M., Ttivedi M. et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. 2010 May;71(5):616-26. doi: 10.4088/JCP.09m05471blu. Epub 2010 Mar 23. 1930 Palomar Point Way, Ste 103, Carlsbad, CA 92008, USA. PMID: 20361916[PubMed - indexed for MEDLINE]
- Vacas M., Del Zar M., Martinuzzo M., et al. Inhibition of human platelet aggregation and thromboxane B2 production by melatonin. Correlation with plasma melatonin levels // J. Pineal Res. - 1991; 11: 135-9
- Viswanathan M., Laitinen J., Saavedra J. Expression of melatonin receptors in arteries involved in thermoregulation // Proc. Natl. Acad. Sci. U.S.A. - 1990; 87: 6200-3
- Медведев В.Э., Епифанов А.В. Инновационный метод терапии депрессий у пациентов с ишемической болезнью сердца // Обозрение психиатрии и мед. психологии им. В.М. Бехтерева. - 2010; 3: 31-6
- Котов А.М., Стоцкий А.Д., Колесников А.Б. Антидепрессанты в кардиологии // Клин. медицина. - 2012; 10: 11-6
补充文件
